Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions.
Adult
Aged
Animals
Antigens, Neoplasm
/ genetics
Antineoplastic Agents
/ pharmacology
Carbonic Anhydrase IX
/ antagonists & inhibitors
Carbonic Anhydrase Inhibitors
/ pharmacology
Carbonic Anhydrases
/ genetics
Cell Line, Tumor
Cell Survival
/ drug effects
Disease Models, Animal
Drug Synergism
Female
Gene Duplication
Gene Expression
Humans
Hydrogen-Ion Concentration
Immunohistochemistry
Leukemia, Myeloid, Acute
/ diagnosis
Male
Middle Aged
Tumor Hypoxia
/ drug effects
Tumor Microenvironment
/ drug effects
Xenograft Model Antitumor Assays
Young Adult
fms-Like Tyrosine Kinase 3
/ genetics
Carbonic Anhydrases
acute myeloid leukemia
drug resistance
hypoxia
pH regulation
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
22
08
2021
accepted:
19
09
2021
pubmed:
19
11
2021
medline:
24
3
2022
entrez:
18
11
2021
Statut:
ppublish
Résumé
Acute myeloid leukaemia (AML) is an aggressive form of blood cancer that carries a dismal prognosis. Several studies suggest that the poor outcome is due to a small fraction of leukaemic cells that elude treatment and survive in specialised, oxygen (O
Identifiants
pubmed: 34791807
doi: 10.1111/jcmm.17027
pmc: PMC8650039
doi:
Substances chimiques
Antigens, Neoplasm
0
Antineoplastic Agents
0
Carbonic Anhydrase Inhibitors
0
FLT3 protein, human
EC 2.7.10.1
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
CA9 protein, human
EC 4.2.1.1
Carbonic Anhydrase IX
EC 4.2.1.1
Carbonic Anhydrases
EC 4.2.1.1
carbonic anhydrase XII
EC 4.2.1.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11039-11052Informations de copyright
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Ther Adv Hematol. 2016 Feb;7(1):40-51
pubmed: 26834953
Cancer Med. 2017 Jan;6(1):288-297
pubmed: 28028936
Nature. 2014 Apr 10;508(7495):269-73
pubmed: 24590072
Oncotarget. 2015 Mar 30;6(9):6776-93
pubmed: 25686827
J Exp Med. 2015 Dec 14;212(13):2223-34
pubmed: 26642852
Stem Cells Transl Med. 2014 Apr;3(4):520-9
pubmed: 24493855
Nat Med. 2000 Dec;6(12):1335-40
pubmed: 11100117
Cancer Cell. 2003 Aug;4(2):133-46
pubmed: 12957288
Oral Oncol. 2012 May;48(5):417-23
pubmed: 22172588
Nature. 1998 Jul 30;394(6692):485-90
pubmed: 9697772
Sci Rep. 2015 Nov 30;5:17550
pubmed: 26617391
J Med Chem. 2019 Apr 25;62(8):4174-4192
pubmed: 30925064
Radiother Oncol. 2013 Sep;108(3):523-8
pubmed: 23849171
Expert Opin Ther Targets. 2015 Jan;19(1):37-54
pubmed: 25231999
J Med Chem. 2005 Jul 28;48(15):4834-41
pubmed: 16033263
J Med Chem. 2011 Mar 24;54(6):1896-902
pubmed: 21361354
World J Gastroenterol. 2016 Sep 28;22(36):8168-77
pubmed: 27688658
Front Genet. 2020 May 27;11:480
pubmed: 32536937
Cancer Lett. 2013 Jun 1;333(1):76-88
pubmed: 23348702
Cancer Discov. 2014 Sep;4(9):998-1013
pubmed: 25185190
Cell Stem Cell. 2010 Aug 6;7(2):150-61
pubmed: 20682444
Cancer Biol Med. 2016 Jun;13(2):248-59
pubmed: 27458532
Clin Cancer Res. 2002 Jul;8(7):2240-5
pubmed: 12114426
Int J Hematol Oncol. 2013 Aug 1;2(4):279-288
pubmed: 24490034
Cancer Metastasis Rev. 2019 Jun;38(1-2):65-77
pubmed: 31076951
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):542-7
pubmed: 25696908
Neuro Oncol. 2008 Apr;10(2):131-8
pubmed: 18322268
Nat Cell Biol. 2013 May;15(5):533-43
pubmed: 23624405
Metabolites. 2018 Feb 28;8(1):
pubmed: 29495652
Haematologica. 2015 Jul;100(7):927-34
pubmed: 25682597
Onco Targets Ther. 2021 Mar 04;14:1707-1718
pubmed: 33692626
Semin Hematol. 2015 Jul;52(3):243-8
pubmed: 26111472
J Cell Mol Med. 2011 Jun;15(6):1239-53
pubmed: 21251211
Sci Rep. 2018 Sep 13;8(1):13759
pubmed: 30214007
FEBS Lett. 2004 Nov 19;577(3):439-45
pubmed: 15556624
Nat Rev Drug Discov. 2008 Feb;7(2):168-81
pubmed: 18167490
Cancer Metastasis Rev. 2007 Jun;26(2):299-310
pubmed: 17415526
J Cell Mol Med. 2021 Dec;25(24):11039-11052
pubmed: 34791807
Eur J Med Chem. 2012 Mar;49:24-40
pubmed: 22305612
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Semin Cancer Biol. 2020 Sep 28;:
pubmed: 33002608
Hypoxia (Auckl). 2015 Dec 11;3:83-92
pubmed: 27774485
Future Med Chem. 2015;7(11):1407-14
pubmed: 26230880
J Enzyme Inhib Med Chem. 2019 Dec;34(1):117-123
pubmed: 30362384
J Clin Invest. 2017 Sep 1;127(9):3484-3495
pubmed: 28825596
Cancer Res. 2011 May 1;71(9):3364-76
pubmed: 21415165
Hematology Am Soc Hematol Educ Program. 2012;2012:35-42
pubmed: 23233558
Int J Cancer. 2011 Apr 1;128(7):1614-23
pubmed: 20521252
PLoS One. 2018 Jul 2;13(7):e0199476
pubmed: 29965974
Oncotarget. 2016 May 31;7(22):33081-95
pubmed: 27105499
Eur J Cell Biol. 2010 Aug;89(8):598-606
pubmed: 20434230
Oncol Rep. 2015 Oct;34(4):1968-76
pubmed: 26252502
Biophys J. 2001 Aug;81(2):685-96
pubmed: 11463617
J Cell Mol Med. 2020 Jul;24(13):7378-7392
pubmed: 32450611
Drug Resist Updat. 2009 Aug-Oct;12(4-5):103-13
pubmed: 19632887
World J Clin Oncol. 2012 Jul 10;3(7):98-103
pubmed: 22787577
Sci Rep. 2017 Feb 08;7:41950
pubmed: 28176818
Am J Clin Oncol. 2020 Jul;43(7):484-490
pubmed: 32251122